Biology of Blood and Marrow Transplantation
Volume 9, Issue 9 , Pages 543-558 , September 2003

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

  • Michael Boeckh

      Affiliations

    • Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington, USA
    • Corresponding Author InformationCorrespondence and reprint requests: Michael Boeckh, MD, Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 8109–1024, USA
    • ,
  • W.Garrett Nichols

      Affiliations

    • Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington, USA
    • ,
  • Genovefa Papanicolaou

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    • ,
  • Robert Rubin

      Affiliations

    • Harvard Medical School, Brigham and Women’s Hospital and Harvard/Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston, Massachusetts, USA
    • ,
  • John R Wingard

      Affiliations

    • University of Florida College of Medicine, Gainesville, Florida, USA
    • ,
  • John Zaia

      Affiliations

    • City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA

Received 17 July 2003 ,Accepted 1 August 2003.

  • Image Result

    Incidence of early (before day 100) versus late (after day 100) cytomegalovirus (CMV) disease by year of hematopoietic stem cell transplantation in seropositive allogeneic recipients (n = 1458). Repri

    Incidence of early (before day 100) versus late (after day 100) cytomegalovirus (CMV) disease by year of hematopoietic stem cell transplantation in seropositive allogeneic recipients (n = 1458). Reprinted with permission [6].

  • Image Result
    Continuum of intensity from nonmyeloablative to myeloablative hematopoietic stem cell transplant-conditioning regimens. ATG indicates antithymocyte globulin; TBI, total body irradiation; MP, melphalan

    Continuum of intensity from nonmyeloablative to myeloablative hematopoietic stem cell transplant-conditioning regimens. ATG indicates antithymocyte globulin; TBI, total body irradiation; MP, melphalan.

  • Image Result
    Incidence of cytomegalovirus disease in high-risk hematopoietic stem cell transplant recipients after nonmyeloablative and myeloablative conditioning regimens. Incidence at day 100, P = .08; incidence

    Incidence of cytomegalovirus disease in high-risk hematopoietic stem cell transplant recipients after nonmyeloablative and myeloablative conditioning regimens. Incidence at day 100, P = .08; incidence at day 365, P = 87; day of onset, P = .02. Reprinted with permission [28].

  • Image Result
    Cumulative incidence of late CMV disease in patients with the presence and absence of risk factors present at 3 months. Right, graft-versus-host disease (GVHD; grade 2–4 or clinical chronic). Left: An

    Cumulative incidence of late CMV disease in patients with the presence and absence of risk factors present at 3 months. Right, graft-versus-host disease (GVHD; grade 2–4 or clinical chronic). Left: Any pp65 antigenemia (AG) before day 95 and CD4 count <50 cells per cubic millimeter. Reprinted with permission [7].

  • Image Result
    Approximate time of CMV infection after allogeneic hematopoietic stem cell transplantation during the era of preemptive treatment strategies with ganciclovir. GCV indicates ganciclovir; FSC, foscarnet

    Approximate time of CMV infection after allogeneic hematopoietic stem cell transplantation during the era of preemptive treatment strategies with ganciclovir. GCV indicates ganciclovir; FSC, foscarnet; IP, interstitial pneumonia; BMT, bone marrow transplantation.

PII: S1083-8791(03)00287-8

doi: 10.1016/S1083-8791(03)00287-8

Biology of Blood and Marrow Transplantation
Volume 9, Issue 9 , Pages 543-558 , September 2003

Article Tools

* Image Usage & Resolution